Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM6A | O15550 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazine SCHEMBL27869246 | 0.94 | NAPRT (0.36) | SMN1; SMN2KDM4ENAPRTHCAR2ALDH1A1 | |
| SCHEMBL8698383 | 0.87 | PARP1 (0.41) | SMN1; SMN2NR4A1NR4A2APOBEC3AAPOBEC3G | |
| SCHEMBL27831516 | 0.86 | SMN1; SMN2 (0.33) | SMN1; SMN2NR4A1NR4A2KDM4EL3MBTL1 | |
| SCHEMBL11846942 | 0.77 | — | — | |
| SCHEMBL298299 | 0.74 | — | — | |
| SCHEMBL27510365 | 0.74 | — | — | |
| SCHEMBL163470 | 0.74 | — | — | |
| SCHEMBL28323931 | 0.74 | ALDH1A1 (0.34) | EGLN1HIF1ANTET2TET1LMNA | |
| SCHEMBL4342320 | 0.73 | — | — | |
| SCHEMBL780236 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019889-B | Visible long afterglow-near infrared double-pass fluorescent anti-counterfeiting ink and preparation method thereof | 当纳利(成都)印刷有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-117358278-A | Monoatomically dispersed Ni-N-C catalyst and preparation method and application thereof | 江苏扬农化工集团有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116404256-B | Electrolyte, battery monomer, battery and electric equipment | 宁德时代新能源科技股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116364907-B | Lithium-rich manganese-based layered cathode material, and preparation method and application thereof | 天津巴莫科技有限责任公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116404256-A | Electrolyte, battery monomer, battery and electric equipment | 宁德时代新能源科技股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-116364907-A | Lithium-rich manganese-based layered cathode material, and preparation method and application thereof | 天津巴莫科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| EP-0000950-A1 | Imidazole derivatives and salts thereof and their synthesis | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | claimed |
| CN-119019889-B | Visible long afterglow-near infrared double-pass fluorescent anti-counterfeiting ink and preparation method thereof | 当纳利(成都)印刷有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119019889-A | Visible long afterglow-near infrared double-pass fluorescent anti-counterfeiting ink and preparation method thereof | 当纳利(成都)印刷有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11926617-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-4639420-A | Method for the immunoanalysis of cholesterol epoxides | SCHAFFNER CARL P (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0203968-A1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES. | SCHAFFNER CARL P | 1986-12-10 | — | — | EP | disclosed |
| WO-1986003299-A1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES | SCHAFFNER CARL P | 1986-06-05 | — | — | WO | disclosed |
| EP-0019067-B1 | 5,10-DIOXO-5,10-DIHYDRODIIMIDAZO(1,5-A,1',5'-D)PYRAZINE-1,6-DICARBOXYLIC ACID AND A PROCESS FOR PRODUCING IMIDAZOLEDICARBOXYLIC ACID AMIDO-DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1982-10-06 | — | — | EP | disclosed |
| US-4317830-A | ANTISHOCK AGENTS, ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0019067-A1 | 5,10-Dioxo-5,10-dihydrodiimidazo(1,5-a,1',5'-d)pyrazine-1,6-dicarboxylic acid and a process for producing imidazoledicarboxylic acid amido-derivatives | AJINOMOTO CO., INC. (JP) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SMN1; SMN2 2329/4885NR4A1 2008/4885NR4A2 3061/4885 |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | SMN1; SMN2 4688/4885NR4A1 552/4885NR4A2 895/4885 |
| US-11926617-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | SMN1; SMN2 4688/4885NR4A1 552/4885NR4A2 895/4885 |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | SMN1; SMN2 2037/4885NR4A1 1597/4885NR4A2 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.